Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 10
Submit an article Journal homepage
493
Views
27
CrossRef citations to date
0
Altmetric
Drug Evaluation

C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease

Francesco Locatelli Direttore Struttura Complessa di Nefrologia e Dialisi, Azienda Ospedaliera di Lecco, Ospedale ‘Alessandro Manzoni’ , Via Dell' Eremo 9/11, 23900 Lecco, Italy +39 034 148 9850; +39 034 148 9860; [email protected]
&
Bruno Reigner Pharma Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
Pages 1649-1661 | Published online: 09 Oct 2007

Bibliography

  • GRASSMAN A, GIOBERGE S, MOELLER S, BROWN G: ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol. Dial. Transplant. (2005) 20:2587-2593.
  • XUE JL, MA JZ, LOUIS TA et al.: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J. Am. Soc. Nephrol. (2001) 12:2753-2758.
  • JACOBS C: Costs and benefits of improving renal failure treatment – where do we go? Nephrol. Dial. Transplant. (2006) 21:2049-2052.
  • MCCLELLAN WM, ARONOFF SL, BOLTON WK: The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Res. Opin. (2004) 20:1501-1510.
  • HÖRL WH, MACDOUGALL IC, ROSSERT J, RUTKOWSKI B, WAUTERS JP, VALDERRÁBANO F: Predialysis survey on anemia management: patient referral. Am. J. Kidney Dis. (2003) 41:49-61.
  • PISONI RL, BRAGG-GRESHAM JL, YOUNG EW et al.: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. (2004) 44:94-111
  • FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC, BARRE PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis. (1996) 28:53-61.
  • PARFREY PS, FOLEY RN, HARNETT JD, KENT GM, MURRAY DC, BARRE PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol. Dial. Transplant. (1996) 11:1277-1285.
  • OBRADOR GT, PEREIRA BJG: Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol. Dial. Transplant. (2002) 17(Suppl. 11):44-46.
  • SILVERBERG D: Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol. Dial. Transplant. (2003) 18(Suppl. 2):ii7-ii12.
  • SILVERBERG D, WEXLER D, BLUM M et al.: Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press. Res. (2005) 28:41-47.
  • SILVERBERG DS, WEXLER D, IAINA A, SCWARTZ D: The interaction between heart failure and other heart diseases, renal failure and anemia. Semin. Nephrol. (2006) 26:296-306.
  • LOCATELLI F, ALJAMA P, BÁRÁNY P et al.: Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. (2004) 19(Suppl. 2):ii1-ii47.
  • NATIONAL KIDNEY FOUNDATION: NKF-K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. (2006) 47(Suppl. 3):S11-S145.
  • ROSS SD, FAHRBACH K, FRAME D, SCHEYE R, CONNELLY JE, GLASPY J: The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin. Ther. (2003) 25:1786-1805.
  • COLLINS AJ: Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol. Dial. Transplant. (2003) 18(Suppl. 2):ii2-ii6.
  • LACSON E Jr, OFSTHUN N, LAZARUS JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am. J. Kidney Dis. (2003) 41:111-124.
  • LOCATELLI F, PISONI RL, AKIZAWA T et al.: Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am. J. Kidney Dis. (2004) 44(Suppl. 2):S27-S33.
  • NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines: 2000 update. Am. J. Kidney Dis. (2001) 37(Suppl. 1):S1-S238.
  • BERNS JS, ELZEIN H, LYNN RI, FISHBANE S, MEISELS IS, DEOREO PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. (2003) 64:1514-1521.
  • COLLINS AJ, BRENNER RM, OFMAN JJ et al.: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am. J. Kidney Dis. (2005) 46:481-488.
  • FISHBANE S, BERNS JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. (2005) 68:1337-1343.
  • FISHBANE S: Recombinant human erythropoietin: has treatment reached its full potential? Semin. Dial. (2006) 19:1-4.
  • GILBERTSON D, EBBEN J, COLLINS A: The effect of hemoglobin variability on hospitalization and mortality. Nephrol. Dial. Transplant. (2006) 21(Suppl. 4):iv169 (Abstract SP458).
  • HALSTENSON CE, MACRES M, KATZ SA et al.: Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin. Pharmacol. Ther. (1991) 50:702-712.
  • MACDOUGALL IC, GRAY SJ, ELSTON O et al.: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. (1999) 10:2392-2395.
  • ROGER SD, COOPER B: What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology (2004) 9:223-228.
  • MACDOUGALL IC, ECKARDT KU: Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet (2006) 368:947-953.
  • JARSCH M, BRANDT M, LANZENDÖRFER M, HASELBECK A: Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin beta determined by surface plasmon resonance and competition binding assay. Pharmacology (2007) (In Press).
  • JARSCH M, KUBBIES M, LANZENDÖRFER M, HASELBECK A, BRANDT M: C.E.R.A. acts differently at the erythropoietin (EPO) receptor compared with epoetin beta: UT-7 and CD34+ cell stimulation assays. J. Am. Soc. Nephrol. (2006) 17:619A (Abstract SA-PO209).
  • REIGNER B, JORDAN P, PANNIER A, GLASPY J: Phase I studies with CERA (continuous erythropoiesis receptor activator), an innovative erythropoietic agent. Eur. J. Cancer (2003) 1(Suppl. 5):S172 (Abstract 568).
  • FISHBANE S, PANNIER A, LIOGIER X et al.: The pharmacokinetic and pharmacodynamic properties of subcutaneous C.E.R.A. (continuous erythropoietin receptor activator) are unaffected by the site of administration. J. Clin. Pharmacol. (2007) (In Press).
  • DOUGHERTY FC, REIGNER B, JORDAN P, PANNIER A: CERA (continuous erythropoiesis receptor activator): dose-response, pharmacokinetics and tolerability in Phase I multiple ascending dose studies. Proc. Am. Soc. Clin. Oncol. (2004) 23:603 (Abstract 6692).
  • MACDOUGALL IC, REIGNER B, DOUGHERTY FC: Consistent pharmacokinetic properties of C.E.R.A. (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD. Am. J. Kidney Dis. (2006) 47:A41 (Abstract 89).
  • MACDOUGALL IC, ROBSON R, OPATRNA S et al.: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. (2006) 1:1211-1215.
  • TSUBAKIHARA Y, BESSHO M, SUZUKI M: Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of intravenous (IV) administrations of C.E.R.A. (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients not on dialysis. Nephrol. Dial. Transplant. (2006) 21(Suppl. 4):iv150 (Abstract SP406).
  • KINDLER J, ECKARDT KU, EHMER B et al.: Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol. Dial. Transplant. (1989) 4:345-349.
  • JENSEN JD, JENSEN LW, MADSEN JK, POULSEN L: The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur. J. Haematol. (1995) 54:111-116.
  • WALRAFEN P, VERDIER F, KADRI Z, CHRETIEN S, LACOMBE C, MAYEUX P: Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood (2005) 105:600-608.
  • DOUGHERTY FC, LEYPOLDT JK, CHEUNG AK, LOGHMAN-ADHAM M: No effect of hemodialysis or hemofiltration on concentrations of CERA (continuous erythropoietin receptor activator): in vitro study results. J. Am. Soc. Nephrol. (2003) 14:A770 (Abstract SU-PO1065).
  • DE FRANCISCO ALM, SULOWICZ W, KLINGER M et al.: Continuous erythropoietin receptor activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, Phase II study. Int. J. Clin. Pract. (2006) 60:1687-1696.
  • PROVENZANO R, BESARAB A, MACDOUGALL IC et al.: The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a Phase II study. Clin. Nephrol. (2007) 67:306-317.
  • DOUGHERTY FC, REIGNER B, BEYER U: Dose-dependent erythropoietic responses to subcutaneous CERA (continuous erythropoietin receptor activator) in a multiple-dose study of dialysis patients with chronic renal anemia. Abstract Book of the XLI ERA-EDTA Congress, Lisbon, Portugal (15 – 18 May 2004):325 (Abstr. MP280).
  • BESARAB A, PROVENZANO, MACDOUGALL IC et al.: Dose-dependent erythropoietic responses to subcutaneous (SC) CERA (continuous erythropoietin receptor activator) in a multi-dose study of patients (pts) with chronic kidney disease (CKD) not on dialysis. J. Am. Soc. Nephrol. (2005) 16:760A (Abstr. SA-PO-930).
  • PROVENZANO R, DOUGHERTY FC: Subcutaneous (SC) CERA (continuous erythropoietin receptor activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis. Am. J. Kidney Dis. (2006) 47:A50 (Abstract 126).
  • BESARAB A, SALIFU MO, LUNDE NM et al.: Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, Phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension Phase in patients with chronic kidney disease. Clin. Ther. (2007) 29:626-639.
  • LOCATELLI F, VILLA G, DE FRANCISCO ALM et al.: Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr. Med. Res. Opin. (2007) 23:969-979.
  • DOUGHERTY FC, LOGHMAN-ADHAM M, SCHULTZE N, BEYER U: Adequate haemoglobin levels are maintained with continuous erythropoietin receptor activator (C.E.R.A.) in dialysis patients regardless of gender, age, race, and diabetic status. Nephrol. Dial. Transplant. (2005) 20(Suppl. 5):v269 (Abstr. MP206).
  • SALIFU M, VILLA G, DOUGHERTY FC: Adequate haemoglobin levels are maintained with continuous erythropoietin receptor activator (C.E.R.A.) in dialysis patients with different ranges of iron status and pre-existing conditions. Am. J. Kidney Dis. (2006) 47:A53 (Abstr. 138).
  • MACDOUGALL IC, WALKER R, PROVENZANO R et al.: C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. J. Am. Soc. Nephrol. (2006) 17:619A (Abstr. SA-PO208).
  • KLINGER M, ARIAS M, VARGEMEZIS V et al.: Efficacy of intravenous C.E.R.A. administered every two weeks compared with epoetin administered three times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am. J. Kidney Dis. (2007) (In Press).
  • CANAUD B, BRAUN J, LOCATELLI F et al.: Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Nephrol. Dial. Transplant. (2006) 21(Suppl. 4):iv157 (Abstr. SP425).
  • LEVIN NW, FISHBANE S, VALDÉS CAÑEDO F et al.; on behalf of the MAXIMA STUDY INVESTIGATORS: The effect of intravenous C.E.R.A. given every 2 or 4 weeks in maintaining stable control of haemoglobin in chronic kidney disease patients on dialysis. Lancet (2007) (In Press).
  • SULOWICZ W, LOCATELLI F, RYCKELYNCK J-P et al.: Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin. J. Am. Soc. Nephrol. (2007) 2:637-646.
  • SPINOWITZ B, COYNE DW, FRATICELLI F et al.: C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre-filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis. J. Am. Soc. Nephrol. (2006) 17:A395 (Abstr. PUB376).
  • JADOUL M, VANRENTERGHEM Y, FORET M, WALKER R, GRAY SJ: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol. Dial. Transplant. (2004) 19:898-903.
  • PROVENZANO R, BHADURI S, SINGH AK: Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin. Nephrol. (2005) 64:113-123.
  • GRZESZCZAK W, SULOWICZ W, RUTKOWSKI B et al.: The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin b in peritoneal dialysis patients with chronic renal anaemia. Nephrol. Dial. Transplant. (2005) 20:936-944.
  • DE COCK E, VAN BELLINGHAM L, STANDAERT B: Assessing provider time for anaemia management of dialysis patients using time and motion methods: a multi-centre observational study in Europe. Value Health (2002) 5:581.
  • CARRERA F, VAN KRIEKINGE G: Estimation of time saved when switching from recombinant human erythropoietin to darbepoetin alfa for the correction of anemia in dialysis patients. J. Am. Soc. Nephrol. (2003) 14:789A (Abstr. PUB075).
  • MOORE T, CHOOKIE S: Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data. Nephrol. Nurs. J. (2005) 32:399-407.
  • WIKSTRÖM B, GUTIERREZ A, JACOBSON S, PRÜTZ K-G, WEISS L: Time gain with every other week administration of erythropoiesis-stimulating agents to patients in hemodialysis. Nephrol. Dial. Transplant. (2006) 21(Suppl. 4):iv166-iv167. (Abstr. SP451).
  • MAHON A, DOCHERTY B: Renal anaemia – the patient experience. EDTA/ERCA J. (2004) 30:34-37.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.